Adicet Bio Inc
NASDAQ:ACET

  • LAST PRICE
    1.3300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.3600/ 7
  • Ask / Lots
    1.4100/ 1
  • Open / Previous Close
    0.0000 / 1.3300
  • Day Range
    ---
  • 52 Week Range
    1.1000
    7.2800
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 12 hours ago by Business Wire
      Companies Mentioned: ACET

      --Presented promising preclinical data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting; on track to file investigational new drug (IND) in renal cell carcinoma in 2Q 2024

    • 12 hours ago by Dow Jones
      Companies Mentioned: ACET
      ---------------------------------- 2024 2023 ----------------- --------------- Operating expenses: Research and development 23,897 26,756 General and administrative 6,974 6,566 ------------ ----------- Total operating expenses 30,871 33,322 ------------ ----------- Loss from operations (30,871) (33,322) Interest income 2,918 2,666 Interest expense (2) (19) Other expense, net (61) (206) ------------ ----------- Loss before income tax provision (28,016) (30,881) Income tax provision -- -- ------------ ----------- Net loss $ (28,016) $ (30,881) ============ =========== Net loss per share, basic and diluted $ (0.35) $ (0.72) ============ =========== Weighted-average common shares used in computing net loss per share, basic and diluted 79,071,652 42,955,688 ============ =========== ADICET BIO, INC. Consolidated Balance Sheets (in thousands) (Unaudited) March 31, December 31, ---------- ---------------- 2024 2023 ---------- ---------------- Cash and cash equivalents $ 247,589 $ 159,711 Working capital 232,889 142,985 Total assets 293,095 207,295 Accumulated deficit (408,788) (380,772) Total stockholders' equity 258,804 170,175

    • 12 hours ago by Dow Jones
      Companies Mentioned: ACET
      2024 2023 ----------------- --------------- Operating expenses: Research and development 23,897 26,756 General and administrative 6,974 6,566 ------------ ----------- Total operating expenses 30,871 33,322 ------------ ----------- Loss from operations (30,871) (33,322) Interest income 2,918 2,666 Interest expense (2) (19) Other expense, net (61) (206) ------------ ----------- Loss before income tax provision (28,016) (30,881) Income tax provision -- -- ------------ ----------- Net loss $ (28,016) $ (30,881) ============ =========== Net loss per share, basic and diluted $ (0.35) $ (0.72) ============ =========== Weighted-average common shares used in computing net loss per share, basic and diluted 79,071,652 42,955,688 ============ =========== ADICET BIO, INC. Consolidated Balance Sheets (in thousands) (Unaudited) March 31, December 31, ---------- ---------------- 2024 2023 ---------- ---------------- Cash and cash equivalents $ 247,589 $ 159,711 Working capital 232,889 142,985 Total assets 293,095 207,295 Accumulated deficit (408,788) (380,772) Total stockholders' equity 258,804 170,175

    • 18 hours ago by Business Wire
      Companies Mentioned: ACET

      Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024.

    • 18 hours ago by Dow Jones
      Companies Mentioned: ACET
      REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--May 14, 2024--
      Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024.

Peers Headlines